(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in the Journal of Obstetrics and Gynecology, linked high survival rates with younger ages, early stages, and tumor type but they also found many exceptions to … Continued
On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.
(8/12/15) In response to the article “An Ovarian Cancer Treatment, Recommended Since 2006, is Found to be Underused,“ published in the Health section of The New York Times on August 3, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, strongly encouraging physicians and treatment centers to fully consider and communicate all treatment … Continued
Gynecologic Cancer Patients to Receive Support in 6 New Locations WEST CHESTER, Pa (August 10, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC today announced six new Woman to Woman grant recipients: Cooper University Hospital, Camden, New Jersey; Shanti Project/Kaiser Permanente, San Francisco, California; Northside Hospital Cancer Center, Atlanta, Georgia; The University of Alabama at … Continued
(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between 2003 and 2012, fewer than 50% of eligible patients received it. Previous studies have shown that the use of IP chemotherapy significantly improves survival among … Continued
2015 marks the 10th anniversary of the Ovarian Cancer Alliance of Oregon and Southwest Washington, a Partner Member organization dedicated to spreading awareness through education, providing support to women and their families, and advocating for awareness and research funding. When Diane Rader O’Conner met Diane Elizondo while undergoing treatment for ovarian cancer, they realized the … Continued
(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that gene therapy that delivers a protein that suppresses the development of female reproductive organs may improve survival rates in patients with ovarian cancer that has … Continued
(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes. Researchers at the University of Texas MD Anderson Cancer Center … Continued
(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early Career Award to Sarah Adams, MD. The benefit of this combination … Continued
(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had a longer time to recurrance, but they had similar overall survival … Continued
QVC and Ovarian Cancer Research Fund Joining Forces for “QVC Presents Super Saturday LIVE” Broadcast WEST CHESTER, Pa. (July 21, 2015) – Help advance the fight against ovarian cancer with stylish steals and dazzling deals. QVC and Ovarian Cancer Research Fund (OCRF) are uniting once again for “QVC Presents Super Saturday LIVE,” an annual designer … Continued
(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of survival, according to a study by researchers at the Rutgers Cancer Institute of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
